Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Jumia Technologies AG - ADR — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Jumia Technologies AG - ADR trades at $6.53 (market cap $900.64M). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 5.2× Jumia Technologies AG - ADR's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Jumia Technologies AG - ADR for 28 Days on average.
| DFTX | JMIA | |
|---|---|---|
Market Cap | $4.71B | $900.64M |
Volume | 1,966,636 | 625,675 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.45 | $14.60 |
52-Week Low | $10.68 | $5.69 |
Typical Hold Time | 0 Days | 28 Days |
Enterprise Value | $3.67B | $866.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JMIA trades at $6.48, down 4.71% today, with bearish technical signals from moving averages. The company shows improving fundamentals with revenue growth from $167M in 2024 to $189M in 2025 and narrowing losses, though it remains unprofitable with a -27.54% net margin. Recent news highlights a $50M capital raise and progress toward EBITDA breakeven by year-end 2026.
Analyst consensus is bullish with a $12 price target (71% buy ratings), but risks include persistent losses, high P/B ratio of 1,014, and negative cash flow from operations. The path to profitability and African market execution are critical for upside realization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
